The peripheral administration of the acetylcholinesterase (AChE) antagonist physostigmine evoked anxiety and depressive symptoms in human subjects by decreasing ACh catabolism and increasing neurotransmitter activities [33]. This evidence concerns the gene ACHE and Anxiety.